BIORAPBiological Research for Animals & People
References in periodicals archive ?
GlaxoSmithKline plc signed a joint drug development agreement with BioRap Technologies Ltd., the transfer company of the Rappaport Family Institute for Research in the Biomedical Sciences at the Technion, Israel Institute of Technology.
GSK and BioRap will commercialize the Israeli company's molecule for the treatment of immune system related disease.
In the first phase, GSK and BioRap will develop 2 product groups for the treatment of Graft-versus-host-disease (GVHD), a potentially lethal side-effect of bone marrow transplants.